Heart Disease is the Second Costliest Ailment for U.S. Employers

Importance of Cancer Prevention and Screenings

Cancer continues to be the top healthcare cost for many employers and their medical plans, according to the Business Group on Health report. Within the U.S., over $200 billion per year is spent on cancer treatments and care. Who’s affected The chances of being diagnosed with cancer are high, with …

FDA Approved 55 New Treatments in 2023

In 2023, the U.S. Food and Drug Administration (FDA) increased their approvals by 50% since 2022, approving 55 new treatments. On average, the FDA typically approves 45-50 drugs every year. The number of approved drugs depends upon the complexity of newly developed drugs and the advancements in the understanding of …

2024 Plan Limits Announced

The Internal Revenue System (IRS) recently announced the 2024-dollar limits for employee benefits including: High Deductible Health Plans (HDHPs), Health Savings Accounts (HSAs), Flexible Spending Accounts (FSAs), transportation benefits, and adoption assistance. As cost-of-living expenses continue to rise due to inflation, the IRS annually adjusts contribution limits to accommodate spending …

Health Plans to Continue Providing Free Preventative Care

2024 Retirement Plan Limits

The Internal Revenue Service (IRS) recently released Notice 2023-75, announcing the cost-of-living adjustments for 2024. These adjustments affect the amounts of money in which employees can contribute to 401(k) plans and individual retirement accounts (IRAs). 2024 limit increases Important 2024 limits announced by the IRS include: The employee contribution limit …

2024 Medicare Amounts

The Centers for Medicare & Medicaid Services (CMS) released the 2024 Medicare Part A and B premiums, deductibles, and coinsurance amounts. Additionally, the 2024 Medicare Part D income-related monthly adjustment amounts were also announced. Medicare Part B Premium and Deductible Physician, outpatient hospital, certain hospital health services, and other medical …

RSV Injection for Infants Approved

RSV Injection for Infants Approved

On July 17, 2023, the Food and Drug Administration approved an injectable drug designed to protect children up to 2 years of age from respiratory syncytial virus (RSV). The Centers for Disease Control and Prevention’s (CDC) Advisory Committee for Immunization Practices is set to meet to determine who should be …